Introduction: The immediate identification of infectious tuberculosis and implementation of effective isolation measures, are a priority of the national policies for disease control.
Objectives: To identify clinical predictor's factors related with sputum smear-positive, in patients with pulmonary tuberculosis diagnosis.
Population And Methods: This was a retrospective study involving 289 patients admitted consecutively with the diagnosis of tuberculosis (ICD-9-CM: 010-018) through the emergency department of a Central Hospital. The study was conducted from January 1999 to December 2005.
Results: 216 patients (74.7%) were identified with pulmonary tuberculosis: mean age 40.3 (SD 16.1); 77.8% males. Of these 179 (82%) were smear-positive and 157 (54.5%) had human immunodeficiency virus (HIV) co-infection. Of the 37 patients with sputum smearnegative 18 (48.6%) had culture positive. The clinical factors that were better related with sputum smear-positive were: cough with sputum (p = 0.031) and classic chest radiograph patterns, parenchymal consolidation (p < 0.001) and cavitation (p = 0.002). HIV co-infection wasn't associated with a higher risk of infectious tuberculosis.
Conclusions: Respiratory symptoms and classic patterns on chest radiograph, were clinical factors better related with a higher probability of sputum smear-positive. In these patients it is a good clinical practice to propose immediate isolation measures even before the results of sputum smear.
Download full-text PDF |
Source |
---|
Int J Infect Dis
December 2024
National Centre for Infectious Diseases, Singapore; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore.
Introduction: Subclinical tuberculosis (TB) is challenging to diagnose due to the lack of a clear definition and symptoms. This study aimed to describe the subclinical disease spectrum among people with culture confirmed pulmonary tuberculosis routinely diagnosed in Singapore, a country with moderate incidence, utilising different definitions. It also aimed to identify risk factors for subclinical TB and the current diagnostic approaches in detecting subclinical TB.
View Article and Find Full Text PDFPLoS One
December 2024
Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Background: Non-tuberculous mycobacteria (NTM) are environmental agents that can cause opportunistic pulmonary disease in humans and animals, often misdiagnosed as tuberculosis (TB). In this study, we describe the cases of NTM identified during the first national anti-TB drug resistance survey conducted in Mali and explore associated risk factors.
Methods: Sputum was collected from people presenting for pulmonary TB diagnosis from April to December 2019, regardless of age.
GMS Hyg Infect Control
November 2024
HBT Medical College and Dr. RN Cooper Hospital Juhu, Mumbai, India.
Introduction: Smoking and tuberculosis are the two major, global health problems. Not only active smokers but also passive smokers are at risk of becoming infected with tuberculosis. Through many mechanisms, smoking decreases immunity and predisposes to numerous infections.
View Article and Find Full Text PDFMicrobiol Spectr
December 2024
Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, China.
Sitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and data demonstrate that sitafloxacin has a potent killing effect against , including drug-resistant strains, which is superior to that of other available quinolones. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. This study aims to evaluate the early bactericidal activity (EBA) of sitafloxacin in patients with primary drug-susceptible tuberculosis.
View Article and Find Full Text PDFBMJ Open
August 2024
Division of HIV/AIDS, World Health Organization, Geneva, Switzerland.
Introduction: Tuberculosis (TB) continues to be one of the deadliest infectious diseases over the centuries, killing more people worldwide than any other single infectious disease. There is an urgent need for additional strategies which can expedite efforts to combat TB including a preventive vaccine. In this endeavour, we have developed a protocol for a multisite, double-blind, placebo-controlled clinical trial in India that aims to evaluate the efficacy and safety of two TB vaccines; namely, VPM1002 and Immuvac () () (MIP) among healthy household contacts (HHCs) of sputum smear-positive pulmonary TB (PTB) patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!